Intuitive Surgical, Inc. (NASDAQ:ISRG) Given Average Rating of “Moderate Buy” by Analysts

Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) have been given an average recommendation of “Moderate Buy” by the twenty-one research firms that are covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, four have issued a hold recommendation and sixteen have given a buy recommendation to the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $613.10.

A number of research firms have recently commented on ISRG. Citigroup raised their price target on Intuitive Surgical from $640.00 to $711.00 and gave the stock a “buy” rating in a report on Friday, January 24th. Stifel Nicolaus raised their target price on Intuitive Surgical from $525.00 to $610.00 and gave the stock a “buy” rating in a research note on Thursday, December 5th. CICC Research began coverage on Intuitive Surgical in a research report on Monday, January 27th. They set a “neutral” rating and a $550.00 price target on the stock. Truist Financial raised their price objective on shares of Intuitive Surgical from $640.00 to $666.00 and gave the company a “buy” rating in a research report on Friday, January 24th. Finally, Erste Group Bank raised shares of Intuitive Surgical from a “hold” rating to a “buy” rating in a report on Tuesday, November 19th.

Insider Buying and Selling

In other news, EVP Myriam Curet sold 2,401 shares of the stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $581.00, for a total transaction of $1,394,981.00. Following the completion of the sale, the executive vice president now owns 353 shares of the company’s stock, valued at approximately $205,093. This represents a 87.18 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Jamie Samath sold 270 shares of Intuitive Surgical stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $540.15, for a total transaction of $145,840.50. Following the completion of the transaction, the chief financial officer now directly owns 8,757 shares in the company, valued at approximately $4,730,093.55. The trade was a 2.99 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 8,077 shares of company stock worth $4,620,025 in the last ninety days. 0.80% of the stock is owned by insiders.

Institutional Trading of Intuitive Surgical

Institutional investors have recently modified their holdings of the company. Brucke Financial Inc. bought a new position in Intuitive Surgical during the 4th quarter valued at approximately $208,000. Bernard Wealth Management Corp. bought a new position in shares of Intuitive Surgical during the fourth quarter valued at approximately $56,000. Capital A Wealth Management LLC purchased a new stake in Intuitive Surgical in the fourth quarter worth $1,045,000. Financial Advisory Corp bought a new stake in Intuitive Surgical in the fourth quarter valued at $258,000. Finally, Integrated Advisors Network LLC increased its position in Intuitive Surgical by 14.0% during the 4th quarter. Integrated Advisors Network LLC now owns 1,998 shares of the medical equipment provider’s stock valued at $1,043,000 after purchasing an additional 245 shares during the period. 83.64% of the stock is currently owned by hedge funds and other institutional investors.

Intuitive Surgical Trading Down 3.0 %

ISRG opened at $563.77 on Friday. Intuitive Surgical has a 12 month low of $364.17 and a 12 month high of $616.00. The company has a market cap of $200.80 billion, a PE ratio of 87.95, a price-to-earnings-growth ratio of 5.85 and a beta of 1.39. The company has a 50 day moving average of $568.89 and a 200 day moving average of $527.90.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.